Holen Sie sich die Stockscreener-App
11.40
2.06%
0.23
Schlusskurs vom Vortag:
$11.17
Offen:
$11.475
24-Stunden-Volumen:
55,165
Relative Volume:
0.24
Marktkapitalisierung:
$226.03M
Einnahmen:
$33.18M
Nettoeinkommen (Verlust:
$-85.15M
KGV:
-3.7932
EPS:
-3.0054
Netto-Cashflow:
$-58.25M
1W Leistung:
+1.51%
1M Leistung:
+2.24%
6M Leistung:
+0.44%
1J Leistung:
-27.43%
1-Tages-Spanne:
$11.37
$11.82
1-Wochen-Bereich:
$10.92
$11.82
52-Wochen-Spanne:
$9.69
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.40 | 221.47M | 33.18M | -85.15M | -58.25M | -3.0054 |
VRTX
Vertex Pharmaceuticals Inc
|
522.64 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.89 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.62 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.08 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Keros Therapeutics Announces Share Repurchase Authorization Program - TipRanks
Keros Therapeutics Announces $5 Million Share Repurchase Authorization - The Manila Times
Keros approves $5M buyback after $20M Takeda milestone; cash runway into H2 2028 - TradingView
Keros Therapeutics announces $5M share repurchase program after Takeda payment - TipRanks
Keros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares. - marketscreener.com
symbol__ Stock Quote Price and Forecast - cnn.com
Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Keros Therapeutics (NASDAQ:KROS): Is Its Pipeline Worth the Risk? - kalkinemedia.com
Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
Keros Therapeutics director Bienaime buys $10,270 in shares By Investing.com - Investing.com South Africa
Keros Therapeutics director Bienaime buys $10,270 in shares - Investing.com
Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? - Yahoo Finance
Man Group plc Purchases Shares of 155,541 Keros Therapeutics, Inc. $KROS - MarketBeat
BlackRock Inc. Buys Shares of 2,794,217 Keros Therapeutics, Inc. $KROS - MarketBeat
127,885 Shares in Keros Therapeutics, Inc. $KROS Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Nantahala Capital Management LLC Takes Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Zacks Research - MarketBeat
Keros Therapeutics director Bienaime buys $10,270 of KROS stock By Investing.com - Investing.com India
Keros Therapeutics director Bienaime buys $10,270 of KROS stock - Investing.com
ADAR1 Capital Management LLC Acquires New Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Pipeline Progress Gains Focus - kalkinemedia.com
Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock - MarketBeat
Keros (KROS) Today: Moves 4.95% Down to $10.55 in the Latest Session; Market Levels: $10.02 and $11.08 Define the Nearby Reference Levels in the Available RecordPut Support - vinanet.vn
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director schedules 551-share sale - Stock Titan
Keros Therapeutics Secures $20 Million Milestone Payment From Takeda - sekbernews.id
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Keros Therapeutics (KROS) Drops 5.25% to $10.1 — Support at $9.59 in FocusEarnings Miss Risk - vinanet.vn
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity? - Yahoo Finance
Understanding Momentum Shifts in (KROS) - Stock Traders Daily
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside - TradingView
BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 - marketscreener.com
KROS Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Investment CostsRevenue Warning Signal - vinanet.vn
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - MarketBeat
Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 90.92% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - qz.com
FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst - MarketBeat
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus - The Globe and Mail
KROS Maintained by Wells Fargo -- Price Target Lowered to $18.00 - GuruFocus
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners - MarketBeat
Keros Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
KEROS THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $30 - Bitget
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeat
Keros Therapeutics 2026: Revenue $0 EPS ($1.45) — 10-Q Summary - TradingView
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Keros Therapeutics Inc-Aktie (KROS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lerner Lorena Raquel | Chief Scientific Officer |
Aug 18 '26 |
Sale |
10.29 |
3,568 |
36,715 |
27,559 |
| Cho Esther | Chief Legal Officer |
Aug 18 '26 |
Sale |
10.29 |
4,485 |
46,151 |
35,770 |
| Newton Charles W. | Director |
Aug 18 '26 |
Sale |
10.30 |
551 |
5,675 |
12,114 |
| BIENAIME JEAN JACQUES | Director |
Aug 17 '26 |
Buy |
10.27 |
1,000 |
10,270 |
19,592 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):